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Background: Subsets of CD4+ T-cells have been proposed to serve differential roles in
the development of atherosclerosis. Some T-cell types are atherogenic (T-helper type 1),
while others are thought to be protective (regulatoryT-cells). Lineage commitment toward
one type of helperT-cell versus another is strongly influenced by the inflammatory context
in which antigens are recognized. Immunization of atherosclerosis-prone mice with low-
density lipoprotein (LDL) or its oxidized derivative (ox-LDL) is known to be atheroprotective.
However, the antigen specificity of the T-cells induced by vaccination and the mechanism
of protection are not known.
Methods: Identification of two peptide fragments (ApoB3501–3516 and ApoB978–993) from
murine ApoB-100 was facilitated using I-Ab prediction models, and their binding to I-Ab
determined. Utilizing a vaccination scheme based on complete and incomplete Freund’s
adjuvant (CFA and IFA) [1×CFA+4× IFA], we immunized Apoe−/−mice with ApoB3501–3516
or ApoB978–993 emulsified in CFA once and subsequently boosted in IFA four times over
15 weeks. Spleens, lymph nodes, and aortas were harvested and evaluated by flow cytom-
etry and real time RT-PCR. Total atherosclerotic plaque burden was determined by aortic
pinning and by aortic root histology.
Results: Mice immunized with ApoB3501–3516 or ApoB978–993 demonstrated 40% reduction
in overall plaque burden when compared to adjuvant-only control mice. Aortic root frozen
sections from ApoB3501–3516 immunized mice showed a >60% reduction in aortic sinus
plaque development. Aortas from both ApoB3501–3516 and ApoB978–993 immunized mice
contained significantly more mRNA for IL-10. Both antigen-specific IgG1 and IgG2c titers
were elevated in ApoB3501–3516 or ApoB978–993 immunized mice, suggesting helper T-cell
immune activity after immunization.
Conclusion: Our data show that MHC Class II restricted ApoB-100 peptides can be
atheroprotective, potentially through a mechanism involving elevated IL-10.
Keywords:T-cell, atherosclerosis, vaccination, inflammation
INTRODUCTION
Improvements in the treatment and prevention of cardiovascu-
lar disease (CVD) resulted in a 30% reduction in its mortality
rate between 1998 and 2008. Despite this, a recent summary state-
ment from the American Heart Association estimates that each
year 785,000 Americans will have a new heart attack, and that
someone dies from a coronary event every 60 s (1). These statistics
underscore the importance of research that seeks to develop novel
therapies in the fight against atherosclerosis.
Recent discoveries suggest that local arterial tissue inflam-
mation is likely a major instigator in the development of ath-
erosclerosis (2–6). This inflammation is mediated, in part, by
local immunologic processes at the site of plaque lesions which
involve both innate and adaptive immunity (2, 6–10). The
antigens in atherosclerosis driving both pro-atherosclerotic and
atheroprotective immune responses are not known with cer-
tainty. Oxidized low-density lipoprotein (LDL) (ox-LDL), and
the lipoprotein portion of LDL (ApoB-100) have been proposed
as candidate antigens (10–13). Recent evidence suggests that
autoantigens are presented to antigen-experienced CD4+ T-cells
by antigen presenting cells (APCs) residing in the atheroscle-
rotic arteries (14). All T-cell subsets (CD4+, CD8+, TCRγδ+,
NKT-cells) have been found in mouse and human plaques (2,
5, 15, 16). In particular, the presence of CD4+FoxP3+ regulatory
T-cells (TREGS) in these plaques (17–19) indicates that inflam-
mation within the plaque is a regulated process, offering hope
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that therapeutics can be designed targeting T-cell function and
differentiation.
Regulatory T-cells are the focus of many studies in athero-
sclerosis because of their atheroprotective potential. TREGS are
reduced in atherosclerotic plaques (18) and in circulating periph-
eral blood of human subjects with CVD (20) compared to healthy
subjects. In murine studies, adoptive transfer of a subset of TREGS
(Tr1 cells, CD4+FoxP3±IL-10+) administered to Apoe−/− mice
showed a significant decrease in pro-atherosclerotic IFN-γ pro-
duction, increased IL-10 production, and significant reduction in
atherosclerotic lesion size when compared with control mice (21).
IL-10, secreted by TREGS, is atheroprotective and protects both
from fatty streak formation and atherosclerotic plaque formation
(15, 22).
Several studies have reported a protective effect of vaccina-
tion with LDL, or ox-LDL, on the development of atheroscle-
rotic plaque (23–25). However, the mechanism by which these
immunizations convey atheroprotection is an ongoing area of
research. One line of investigation suggests that protective autoan-
tibodies generated during immunization with ox-LDL might be
the source of atheroprotection (24, 26, 27). This was initially a
promising hypothesis which subsequently led to the search for
atheroprotective B-cell (antibody) epitopes. The discovery of such
epitopes was first reported by Fredrikson et al. (28) in 2003. These
researchers assessed the binding of endogenous antibodies (from
pooled human plasma in a case-control cohort of patients with
a history of acute coronary heart events) and identified several
epitope sequences from human ApoB-100 that bound to endoge-
nous human antibodies. Since then several of these peptides
have been used to vaccinate mice, including P2 (TRFKHLRKY-
TYNYEAESSS) (29), P143 (IALDDAKINFNEKLSQLQTY) (30),
and P210 (KTTKQSFDLSVKAQYKKNKH) (30) each conferring
~40–60% atheroprotection. While the original premise of immu-
nizing with B-cell epitopes was atheroprotection via an increase in
peptide-specific antibody levels, this was eventually determined to
not be the case (31).
More recently, researchers have sought to describe the changes
in cellular (rather than humoral) immunity that may result from
immunization with B-cell epitopes from ApoB-100. Several recent
papers have reported an increase in FoxP3+ expressing TREGS
in secondary lymphoid organs [spleens (32) and lymph nodes
(33)] after immunization of mice with P210. While these find-
ings are consistent with reports that suggest TREGS might be
protective in atherosclerosis (17–19), it is unclear how T-cells
can be directly affected by vaccination with peptide sequences
originally recognized as B-cell epitopes. This is especially pecu-
liar in the case of P210, which has been shown not to bind
to I-Ab (the MHC Class II allele expressed by both Apoe−/−
and LDL-R−/− mice) (34), which is a prerequisite for any direct
interaction with T-cell receptors. Subsequent studies have further
described the changes to the T-cell compartment after immuniza-
tion with B-cell epitopes (in particular the CD4+CD25+FoxP3+
TREG population) (35). However, there are currently no T-cell
epitopes related to atherosclerosis that have been described.
Knowledge of such epitopes would help to better characterize T-
cell phenotypes after peptide immunization in the treatment of
atherosclerosis.
The existence of atherosclerosis-related CD4+ T-cell epitopes is
suggested by several experiments. First, human CD4+ T-cell clones
derived from atherosclerotic plaques responded to incubation with
ox-LDL and autologous monocytes (acting as APCs) by prolifer-
ation and production of cytokine (IFNγ) in an antigen-specific,
HLA-DR-restricted manner (11). More recently, live-cell imaging
of explanted aortas from CD11cYFPApoe−/− mice after 12 weeks
of western diet (WD) showed that activated CD44hiCD62Llo
Apoe−/− CD4+ T-cells isolated from Apoe−/− mice, but not wild-
type mice, productively interacted with CD11c-YFP+ APCs in
the aortic wall (14). These T-cells were effector-memory CD4+
T-cells, had long interactions with APCs in the vessel wall and
slowed migration speeds compared to T-cells isolated from naïve
wild-type C57BL/6 mice. Furthermore, the “productiveness” of
these interactions was demonstrated by increased T-cell prolifera-
tion and induction of the pro-inflammatory TH1 cytokines (IFNγ
and TNF). These data suggest that endogenous T-cell antigens are
presented in the aortic wall. It is therefore reasonable to suspect
that these interactions may be promoting, or inhibiting, athero-
sclerosis by driving effector T-cell or regulatory T-cell responses,
respectively. Manipulation of either these antigens or the T-cells
that respond to these antigens would be of great therapeutic value.
Here, we report the discovery of two novel MHC-II restricted
peptides identified in the murine ApoB-100 molecule. These pep-
tides have high affinity for I-Ab (the MHC class II molecule in
C57BL/6 mice), and injection of these two peptides into Apoe−/−
mice in complete Freund’s adjuvant (CFA), followed by four boosts
in incomplete Freund’s adjuvant (IFA), reduces atherosclerosis.
These data suggest that atheroprotective CD4+ T-cell vaccines can
be developed.
MATERIALS AND METHODS
MICE
Eight-week-old female Apoe−/− mice on C57BL/6 background
were purchased from Jackson Laboratories (Bar Harbor, ME,
USA). Mice were housed in a specific pathogen free environment
and fed chow diet until 10 weeks of age. At 10 weeks of age, mice
were started on WD (adjusted calories diet with 42% from fat,
Harlan Labs Cat #: TD.88137, CA, USA) and remained on WD
until sacrifice at 23 weeks old.
PEPTIDES
Using previously described algorithms (36–38) for predicting I-Ab
(MHC Class II) peptide binding motifs in a protein molecule, we
scanned the entire 4505 amino acid sequence of murine ApoB-100
and identified candidate sequences based solely on matches for I-
Ab binding. Six of these were selected based on favorable anchor
residue and hydrophobicity profiles. These sequences are listed in
Table 1. Although the minimal sequence to bind to the MHC Class
II peptide groove is a 9-mer, all peptides were custom synthesized
(Genemed Synthesis, Inc., San Antonio, TX, USA) as 15-mers to
build “ends” on to the peptides for better binding. Peptides were
synthesized in 0.1% trifluoroacetic acid (TFA) for sterility.
I-AB BINDING AFFINITY ASSAY
We measured I-Ab binding affinity using a classical competi-
tive inhibition assay utilizing purified MHC and high affinity
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Table 1 | Peptide sequences and I-Ab binding affinity as determined by
IC50.
Peptide sequences Mouse ApoB-100 position H-2 I-Ab (IC50 nM)
NNYALFLSPRAQQAS 4505–4520 1295
SRATLYALSHAVNSY 438–453 1368
SQEYSGSVANEANVY 3501–3516 4.3
YENFAASNKLDVTFS 1578–1593 ∞
HLEYVSSELRKSLQV 4054–4069 22176
TGAYSNASSTESASY 978–993 7.3
GWYRSPFSRVVHLY MOG38–51 354
ISQAVHAAHAEINE OVA324–337 400
MOG, Mus musculus myelin oligodendrocyte glycoprotein; OVA, Gallus gallus
ovalbumin. Bold font indicates ApoB3501–3516 and ApoB978–993.
radio-labeled I-Ab ligands (39). Their ability to displace the
radio-labeled I-Ab ligand was measured, and an inhibitory con-
centration required to displace 50% of the radio-labeled ligand
(IC50) was determined. Under the conditions utilized, where
(label)< (MHC) and IC50≥ (MHC), the measured IC50 values
are reasonable approximations of the true K d values.
ANTIGEN-SPECIFIC PROLIFERATION
Peptides were emulsified in CFA and mice were immunized
with 200µg of peptide subcutaneously. Ten days later, draining
lymph node cells were harvested and single cell suspensions were
made. 5× 105 viable cells per microtiter well were cultured with
100µg/mL of relevant (or irrelevant) peptide for 4 days. Puri-
fied protein derivative (PPD) served as a positive control. Sixteen
hours before harvesting, 1 mCi of tritiated thymidine (3H) was
added to each well. Cells were harvested and incorporation of 3H
was determined in a scintillation counter. Results are expressed as
stimulation index using the following formula:
Stimulation index (SI)
= cpm experimental − cpm media control
cpm media control
ATHEROPROTECTIVE IMMUNIZATION
Previous work (25) has shown that atheroprotection through
immunization could be achieved by injecting mice with LDL (or
ox-LDL) with a combination of CFA initially, followed by antigen
in IFA for booster immunizations. Using the same immuniza-
tion model, 50µg of ApoB3501–3516 or ApoB978–993 (diluted in
PBS) was emulsified in equal volumes of CFA (BD Difco, Sparks,
MD, USA) and injected into the subcutaneous inguinal area at
8 weeks of age. Repeated boosters with 25µg of ApoB3501–3516 or
ApoB978–993 emulsified in IFA (BD Difco, Sparks, MD, USA) were
administered intraperitoneally at age 12, 16, 20, and 22 weeks.
This immunization scheme will be referred to as 1× CFA+ 4×
IFA for the remainder of this manuscript. Mice were sacrificed
at age 23 weeks and organs were harvested for analysis. Control
immunizations with PBS emulsified in CFA and IFA were also
performed. MOG35–55 [MEVGWYRSPFSRVVHLYRNGK, (40)]
immunizations were also done under identical conditions with
the same adjuvants.
ATHEROSCLEROSIS QUANTIFICATION
Aortic root sections were examined as follows. Hearts were har-
vested, placed in Optimal Cutting Temperature medium (OCT,
Electron Microscopy Sciences, Hatfield, PA, USA), and frozen at
−80°C. Beginning at the first appearance of the tri-leaflet aortic
valve, successive 5µm transverse sections were made for a dis-
tance of 100µm. From these, we analyzed every other section, for
a total of 10 sections per root. Sections were then stained with Oil
Red O and counter-stained with hematoxylin. Extent of athero-
sclerosis was then determined as the area involved on each section.
To measure en face lesion formation, the whole aorta was care-
fully cleaned in situ and then the whole aorta pinned out after
paraformaldehyde incubation at RT for at least 2 h. Staining for
atherosclerotic plaque was performed by incubating samples in
Sudan IV. Quantification was performed using ImagePro software
(Media Cybernetics, Rockville, MD, USA).
LIPID ANALYSIS
Mouse whole blood was collected by cardiac heart puncture during
organ harvest. No anticoagulant was used. The blood was placed
on ice for at least 3–6 h, and then spun at 6300 rpm for 15 min
at 4°C. The supernatant was collected and frozen at −80°C until
analysis to reduce multiple freeze/thaw cycles. Individual sam-
ples were then analyzed by Roche COBAS 8000 Analyzer (Roche
Diagnostics, Indianapolis, IN, USA).
MEASUREMENT OF ANTIBODY TITERS TO ApoB3501–3516 AND ApoB978–993
Antibody titers in plasma were determined by chemiluminescent
enzyme immunoassay as previously described (41). In brief, white
“U” bottom plates (Thermo Lab systems, USA) were coated with
various antigens at 5µg/mL in PBS for overnight incubation. Fol-
lowing blocking with 1% BSA-TBS serum was added in increasing
dilutions and incubated at RT for 90 min. Bound antibodies levels
were detected using appropriate alkaline phosphatase-conjugated
secondary antibodies and a 50% aqueous solution of LumiPhos
530 (Lumigen, USA). Data are expressed as relative light units
counted per 100 ms (RLU/100 ms).
FLOW CYTOMETRY
Aortas, lymph nodes, and spleens were digested as previously
described (42). Aortic cell suspensions, spleens, and lymph nodes
were individually pressed through a 70-µm filter and incubated
for 30–60 min in complete RPMI to encourage CD4 re-expression.
Approximately (1–2)× 106 cells were then placed into 96-well
round bottom plates and incubated for 5 min with Fc Block
(1:200), and subsequently stained with primary antibody [CD45-
PerCP 1:50 (BioLegend, San Diego, CA, USA, Cat#103130), CD4-
PE-Cy7 1:50 (eBioscience, San Diego, CA, USA, Cat#25-0041-82),
TCRβ-AF700 1:50 (BioLegend, Cat#109224), and Live/Dead Aqua
1:200 (Invitrogen, Grand Island, NY, USA, Cat# L34957)] for
45–60 min. Plates were washed twice and then incubated with
Fix/Perm buffer solution (eBioscience, Cat# 00-5523-00) for addi-
tional 30 min. Plates were again washed twice with a permeabi-
lization buffer prior to intracellular staining with intracellular
transcription factor staining [FoxP3-efluor450 1:50 (eBioscience,
Cat# 48-5773-82)]. Intracellular staining was performed for 30–
45 min and plates were washed twice with permeabilization buffer
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solution. Samples were analyzed by LSR-II (BD Biosciences, San
Jose, CA, USA). Data was acquired on FACSDiva software (BD
Biosciences) and analyzed by FlowJo (Ashland, OH, USA).
QUANTITATIVE RT-PCR
Spleens, lymph nodes, and aortas were placed in 50µL of
RNALater from Qiagen (Valencia, CA, USA) immediately after
harvest. QIAShredder kit (Valencia, CA, USA) was used to homog-
enize each sample after Trizol treatment. RNA extraction per-
formed using RNeasy Mini kit (Valencia, CA, USA). RNA was
converted to cDNA using iScript Reverse Transcription kit for RT-
qPCR (BioRad, Hercules, CA, USA). Primers were commercially
obtained as part of a Taqman PCR kit (Life Technologies, New
York, NY, USA), and included CD4, IFNγ, TNFα, IL-2, IL-4, IL-10,
IL-17A, Tbx21 (Tbet), GATA3, RORγT, and FoxP3. Housekeeping
genes used in the analysis were one of two ribosomal proteins,
Rpl32 or Rpl13A.
STATISTICAL ANALYSIS
Between groups analysis was performed by one-way ANOVA. Data
are expressed as mean± SEM. P-values <0.05 were considered
significant.
RESULTS
IDENTIFYING CANDIDATE EPITOPES ApoB3501–3516 AND ApoB978–993
A peptide can only be recognized by a CD4+ helper T-cell if it is
bound to MHC class II. Because Apoe−/− mice are on a C57B/6
background, candidate epitopes must be able to bind to the Class
II allele, I-Ab. Previously, it has been shown that I-Ab binding
motifs can be predicted using algorithms based on the number of
anchor residues and hydrophobicity (36–38). We measured I-Ab
binding affinity of six candidate peptides predicted by these algo-
rithms. The binding affinity is reflected by the amount of peptide,
in nanomoles, needed to inhibit binding of a standardized radio-
labeled peptide by 50% (the IC50) (39). Of the six peptides synthe-
sized, only ApoB3501–3516 and ApoB978–993 bound I-Ab with signif-
icant affinity (Table 1, ApoB3501–3516 IC50= 4.3 nM, ApoB978–99
IC50= 7.3 nM). Peptides containing only parts of these sequences
showed reduced binding affinities (Table 2). By comparison, the
known T-cell epitopes OVA324–337 and MOG38–51 (truncated form
of MOG35–55, i.e., myelin oligodendrocyte glycoprotein) have an
IC50 of 400 nM (43) and 354 nM (44), respectively (Table 1).
Based on these binding affinities, the remainder of this work was
performed using ApoB3501–3516 and ApoB978–993.
ANTIGEN-SPECIFIC T-CELL PROLIFERATIVE RESPONSES
Two hundred micrograms (total) of either ApoB3501–3516 or
ApoB978–993 (emulsified in CFA) were injected subcutaneously
into four sites in the flanks. After 10 days the draining lymph nodes
were harvested, and single cell suspensions were incubated for
10 days with 100µg/mL of either ApoB3501–3516 or ApoB978–993
(or irrelevant, MOG35–55) peptide for 4 days. PPD served as a
positive control. Proliferation was measured by 3H incorpora-
tion and expressed as SI. After a single immunization of either
ApoB3501–3516 or ApoB978–993 in CFA, antigen-specific T-cell pro-
liferation was observed when relevant peptide or PPD is added, but
not when irrelevant peptide is added (Table S1 in Supplementary
Material).
Table 2 | I-Ab binding affinity of ApoB3501–3516 and ApoB978–993-related
peptides.
Peptide Sequence Len Pos H-2 I-Ab
(IC50 nM)
ApoB3501–3516 SFTKGNIKSSFLSQEY 16 3489 1169
SSFLSQEYSGSVANEA 16 3497 6.8
SQEYSGSVANEANVY 15 3501 4.3
SGSVANEANVYLNSKG 16 3505 172
NVYLNSKGTRSSVRLQ 16 3513 907
ApoB978–993 LFTGMNYCTTGAYSNA 16 969 655
TTGAYSNASSTESASY 16 977 17
TGAYSNASSTESASY 15 978 7.3
SSTESASYYPLTGDTR 16 985 1258
Sequence of ApoB3501–3516 and ApoB978–993 indicated in boldface.
IMMUNIZATION WITH ApoB3501–3516 AND ApoB978–993
ApoB3501–3516 or ApoB978–993 were each used to vaccinate 10–
14 female Apoe−/− mice. Fifty micrograms of ApoB3501−3516
or ApoB978−993 emulsified in CFA were subcutaneously injected
above the inguinal LN at 8 weeks of age. A WD was then started at
10 weeks of age. Repeated boosters with 25µg of ApoB3501−3516
or ApoB978−993 emulsified in IFA were administered intraperi-
toneally at age 12, 16, 20, and 22 weeks (Figure 1A). Mice were
sacrificed at age 23 weeks of age (13 weeks WD) and organs were
harvested for analysis. Control immunizations with adjuvant only
(1× CFA+ 4× IFA) and an irrelevant peptide (MOG35–55) were
done under identical conditions.
CHOLESTEROL LEVELS
Western diet-fed Apoe−/− mice exposed to the PBS plus 1×
CFA+ 4× IFA regimen had significantly decreased total plasma
cholesterol from 1292 to 960 mg/dL, HDL from 246 to 168 mg/dL,
and non-HDL from 1046 to 797 mg/dL, and triglycerides from 203
to 183 mg/dL compared to WD-fed Apoe−/− mice not exposed to
adjuvant. Similar observations have been reported in other studies
(45). However, none of the mice immunized with ApoB3501–3516
or ApoB978–993 had plasma lipid levels different than the PBS plus
1× CFA+ 4× IFA controls (Table 3). Therefore, all subsequent
statistical analyses were performed without the untreated group.
IMMUNIZATION WITH EITHER ApoB3501–3516 OR ApoB978–993 RESULTS IN
LESS ATHEROSCLEROTIC PLAQUE WHEN USED IN AN IMMUNIZATION
SCHEME USING BOTH CFA AND IFA
Both ApoB3501–3516 and ApoB978–993-treated mice showed ~40%
reduction in en face lesion size by Sudan IV staining of whole
aortas when compared with PBS and MOG35–55 (Figures 1B,C)
immunized mice. Aortic root lesions were also examined for
plaque burden by oil red O (ORO) staining. ApoB3501–3516 immu-
nized mice had >60% reduction (p< 0.01) in overall aortic sinus
plaque development compared to 1× CFA+ 4× IFA (adjuvant-
only treated) mice (Figures 1D,E). ApoB978–993 immunized mice
showed no significant reduction in aortic root plaque burden.
MOG35–55 immunized mice showed no significant decrease. These
data demonstrate that immunization with I-Ab restricted peptide
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FIGURE 1 | Atherosclerosis is decreased in ApoB3501–3516 and
ApoB978–993-treated mice compared to controls. (A) Vaccination
schedule: 8-week-old female Apoe−/− mice were immunized once with
either PBS or peptide in CFA, then boosted four more times with PBS
or peptide in IFA. WD was maintained for 13 weeks. Mice were
sacrificed and organs harvested at 23 weeks of age. (B,C) Results of
aortic pinning analysis after Sudan IV staining are shown with
representative photographs. N =12–15 in each group, *p<0.05 when
compared to 1× CFA+4× IFA group. (D) Representative aortic root
staining sections after ORO staining, counter-stained with hematoxylin.
(E) Plaque area from aortic roots stained from each group. Lesion sizes
from 30 to 40µm distal to start of the aortic valve were averaged per
group. N =5 in each group, *p<0.05 when compared to 1× CFA+1×
IFA control group.
Table 3 | Lipid profile of mice.
Untreated PBS ApoB3501–3516 ApoB978–993 MOG35–55
TC (mg/dL) 1292.0±145.9* 960.3±100.5 870.4±103.6 835.2±108.3 1014.7±76.4
HDL (mg/dL) 245.7±90.9* 167.7±34.6 202.1±23.8 170.3±6.9 213±7.5
Non-HDL (mg/dL) 1046.3±105.8* 796.6±119.3 663.7±124.7 592.2±187.1 801.7±72.4
TG (mg/dL) 203.3±21.0* 182.6±21.9 158.1±32.5 144.7±37.3 142.3±33.2
Weight (g) 26.8±2.2 25.4±1.9 26.3±1.8 25.9±2.1 25.3±1.1
N=6–7 per group, presented as mean±SD.
*p<0.05 when untreated group is compared to groups exposed to adjuvant.
fragments from murine ApoB-100 can reduce plaque burden in
Apoe−/− mice.
IMMUNIZATION WITH EITHER ApoB3501–3516 OR ApoB978–993 RESULTS IN
PEPTIDE-SPECIFIC IgG TITERS
One possible mechanism of atheroprotection is the development
of protective antibodies (24). The production of IgG requires
antigen-specific T-cell help and gives insight into antigen-specific
T-cell activation and lineage bias. IgG1 is a marker of T-helper
type 2 (TH2) activity and IgG2c of T-helper type 1 (TH1)
activity in C57BL/6 mice, which do not express IgG2a (25).
Pooled plasma from each group was analyzed for immunoglobulin
titers by formal antibody dilution curves using chemilumines-
cent ELISA (Figure S1 in Supplementary Material). As shown in
Figures 2A,B for the 1:250 dilution, as expected IgG responses
to ApoB3501–3516 and ApoB978–993 peptides were detected in
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FIGURE 2 | Specific antibody titers after immunization. Sera from 9 to
10 animals per group were pooled and formal antibody dilution curves were
measured by chemiluminescent ELISA against each of the antigens. Shown
here are comparative binding data at serum dilutions of 1:250 and in each
case, values shown are the fold increase compared to values found with
pooled sera from 1× CFA+4× IFA group. (A) IgG1 titers against
ApoB3501–3516 and ApoB978–993. (B) IgG2c titers against ApoB3501–3516 and
ApoB978–993. (C) IgG1 and IgG2c titers against MOG35–55 in MOG35–55
immunized mice. IgG1 and IgG2c titers against (D) native (unmodified) LDL
and (E) MDA (oxidized)-LDL.
ApoB3501–3516 and ApoB978–993 immunized mice, respectively.
Their responses showed complete peptide specificity, with strong
responses in both the Th1 and Th2 helper T-cell compart-
ments. Total IgG1 and IgG2c antibody levels (not antigen-specific)
were similar across all groups (data not shown). MOG35–55
immunization produced a predominantly IgG2c response to
MOG35–55 (Figure 2C), but no antibody titers to ApoB3501–3516
or ApoB978–993 were detected (Figures 2A,B). 1× CFA+ 4× IFA
immunized mice did not have detectable levels of IgG1 or IgG2c
against ApoB3501–3516 or ApoB978–993 (Figures 2A,B). None of the
immunized mice had elevated IgG titers against native LDL or
MDA-LDL compared to adjuvant only (Figures 2D,E).
REDUCED ATHEROSCLEROTIC PLAQUE BURDEN DOES NOT CORRELATE
WITH AN INCREASE IN THE NUMBER OF FoxP3-EXPRESSING CELLS
Another possible mechanism of atheroprotection conveyed by
immunization with ApoB3501–3516 or ApoB978–993 could be related
to increased numbers of FoxP3-expressing regulatory T-cells.
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FIGURE 3 | FoxP3+ T-cells are not found in increased numbers in
ApoB3501–3516 or ApoB978–993 immunized mice. (A) The lymphocyte
population was captured via forward scatter (FSC) and side scatter (SSC)
gating as shown in Region 1 (R1). Live CD45+ cells were isolated (R2), of
which TCRβ+/CD4+ cells were selected (R3) and examined for their
expression of FoxP3+. Analysis of a representative aorta is shown.
(B) Percentage of aortic FoxP3+ cells within the CD4+/TCRβ+ population.
(C) Percentage of para-aortic lymph node FoxP3+ cells within the
CD4+/TCRβ+ population. (D) Percentage of splenic FoxP3+ cells within the
CD4+/TCRβ+ population. (E) Percentage of non-draining lymph nodes
(pooled from inguinal, axillary, mesenteric) FoxP3+ cells within the
CD4+/TCRβ+ population (N =4–5 in each group).
Whole aortas, along with spleens and lymph nodes (para-aortic,
inguinal, axillary, mesenteric) were harvested from immunized
mice at the time of sacrifice. There were no significant differ-
ences in FoxP3+ cells within the CD4+/TCRβ+ cell population in
the aorta (Figures 3A,B), para-aortic lymph nodes (Figure 3C),
spleens (Figure 3D), or non-draining lymph nodes (inguinal, axil-
lary, mesenteric; Figure 3E) when ApoB3501–3516 and ApoB978–993
were compared to the 1× CFA+ 4× IFA control group.
IMMUNIZATION WITH ApoB3501–3516 OR ApoB978–993 INCREASES mRNA
EXPRESSION OF THE ATHEROPROTECTIVE CYTOKINE, IL-10
RT-PCR analysis of spleens, lymph nodes, and aortas of mice from
each group were analyzed for mRNA expression levels of the TH1
cytokines IFNγ, TNFα, and the TH1 transcription factor Tbx21
(Tbet), the TH2 cytokines IL-4, IL-10, and the TH2 transcription
factor GATA3, the TH17 cytokine IL-17A, and the TH17 transcrip-
tion factor RORγT, and the regulatory T-cell transcription factor
www.frontiersin.org December 2013 | Volume 4 | Article 493 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tse et al. Atheroprotection from MHC-II restricted peptides
FIGURE 4 | Real time RT-PCR analysis of IL-10 mRNA expression.
Organs were harvested and immediately placed into RNA stabilization
reagent, and frozen at −80°C. IL-10 mRNA expression from (A) aortas,
(B) para-aortic lymph nodes, (C) spleens, and (D) non-draining lymph
nodes are shown. *p<0.05 compared to 1× CFA+4× IFA. N =3–5 in
each group.
FoxP3. No significant differences were found except in aortas of
ApoB3501–3516 and ApoB978–993 immunized mice where a signif-
icant increase in IL-10 mRNA expression was noted (p< 0.05)
compared to 1×CFA+ 4× IFA treated and MOG35–55 immunized
control mice (Figures 4A–D). There was no significant difference
in mRNA expression of any other cytokine (IFNγ, TNFα, IL-4, or
IL-17A) or transcription factor (Tbet, GATA3, RORγT, or FoxP3)
examined between groups in any organ (data not shown).
DISCUSSION
Our results show that MHC Class II restricted CD4+ T-cell pep-
tides from the ApoB-100 are effective at reducing atherosclerotic
plaque burden in Apoe−/−mice. ApoB3501–3516 or ApoB978–993 are
high affinity binders for MHC Class II (I-Ab). This is the first publi-
cation to identify such peptides within an atherosclerosis-relevant
protein (ApoB-100).
T-cell responses to vaccination with either (ox)LDL or peptide
epitopes from ApoB-100 have become an area of great interest
because they may enable the development of a vaccine for clin-
ical use. Recent reports have suggested that immunization with
an epitope from ApoB-100 that binds to serum antibodies, P210,
results in atheroprotection via an increase in TREGS (32,33),but the
mechanism by which a B-cell epitope could induce TREGS was not
elucidated. It is not known whether these TREGS are causally related
to the atheroprotection that is observed. In fact, P210 does not bind
to I-Ab (34), suggesting that any actions immunizing with P210
might have are highly unlikely to be related to CD4+ helper T-cells.
One publication has instead suggested that the observed athero-
protection is a result of enhanced CD8+ cytotoxic T-cell activity
against dendritic cells leading to a decreased number of CD11c+
cells within the aorta, and thus reduced atherosclerosis (46). These
researchers demonstrated that adoptive transfer of P210 primed
CD8+ T-cells recapitulated the atheroprotective response in naïve
mice. These contrasting views of how immunization may result
in atheroprotection highlight the need for systematic studies into
MHC-restricted peptide vaccinations.
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Mice immunized with ApoB3501–3516 or ApoB978–993 in the con-
text of CFA and IFA show increased IL-10 mRNA expression levels
in the aortas, significantly above control mice. Since this increased
expression is not associated with an increased in the percent of aor-
tic FoxP3+ regulatory T-cells, we speculate that the IL-10 mRNA
may be derived from FoxP3− Tr1 cells (47, 48) (i.e., one subset of
inducible TREGS) or from myeloid cells (49). While both IFNγ and
IL-17A have been implicated as pro-atherosclerotic cytokines, no
changes in mRNA expression of either cytokine was observed in
the aortas, lymph nodes, or spleens of immunized mice compared
to controls.
We did not detect IgG1 or IgG2c antibody titers to
ApoB3501–3516 or ApoB978–993 in non-immunized mice. This is
despite highly elevated plasma cholesterol levels in Apoe−/− mice
(50). One possibility is that ApoB3501–3516 and ApoB978–993 may
not be naturally processed products of APCs. Another possibility is
that the endogenous forms of ApoB3501–3516 and ApoB978–993 are
not presented efficiently or in high enough quantities by APCs.
Further investigations into the mechanism of atheroprotection
will provide new targets for therapy and prevention of atheroscle-
rosis. It is our hope that these two peptides, and future peptides
that can be discovered by the described immunologic methods,
will lead to a new frontier in atherosclerosis research and ultimately
provide a treatment for this worldwide epidemic.
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Figure S1 | Specific antibody dilution curves. Antibody specific titers were
measured by formal antibody dilution curves using chemiluminescent ELISA.
Dilutions of 1:50 (when possible), 1:250, 1:2500 and 1:6250 were performed.
Baseline group (blue line) represents pooled serum from two female Apoe−/−
mice at 8 weeks of age on chow diet, without immunization. The untreated
group (green line) represents 9–10 female Apoe−/− mice fed western diet for
13 weeks, starting at 10 weeks of age but without any immunizations. Data are
expressed as relative light units counted per 100 ms (RLU/100 ms). (A) IgG1
titers to ApoB3501–3516, ApoB978–993, and MOG35–55. (B) IgG2c titers to ApoB3501–3516,
ApoB978–993, and MOG35–55. (C) IgG1 and IgG2c titers to native (unmodified) LDL.
(D) IgG1 and IgG2c titers to MDA(oxidized)-LDL.
Table S1 | Antigen-specificT-cell proliferation. Mice were immunized with
either ApoB3501–3516, ApoB978–993, PPD (positive control), or MOG35–55 (negative
control). Draining lymph node cells were harvested 10 days later and incubated
with the relevant peptide, PPD or MOG35–55. Proliferative responses were
measured by 3H incorporation and expressed as SI. We show here that there
are antigen-specific T-cell responses to both ApoB3501–3516 and ApoB978–993.
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